secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2023-01-26T23:59:59+00:00
Accession:  0001193125-23-016245
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies
-------------------------------------------------------------------------------

- SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.
- FDA clearance allows first-in-human study in patients with B-cell lymphomas and leukemias.
- Company expects initial clinical data from SC291 study later in 2023.
- Plans to submit a second IND this year for SC262, a CD22-targeted allogeneic CAR T therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/0001193125-23-016245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312523016245/d642303d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-016245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer